📊 PYXS Key Takeaways
Is Pyxis Oncology, Inc. (PYXS) a Good Investment?
Pyxis Oncology faces critical liquidity crisis with less than 3 months of cash runway at current burn rates ($26M annual operating cash burn versus $5.8M cash on hand). Revenue is declining 14.2% YoY while operating losses of $24.4M persist, indicating failed commercialization and inability to control costs. The company will require imminent dilutive capital raises or faces potential restructuring.
Pyxis Oncology, Inc. Key Strengths (PYXS)
- Zero long-term debt (Debt/Equity 0.00x) eliminates financial leverage risk and refinancing concerns
- Adequate working capital coverage with 2.76x current ratio provides near-term operational flexibility
- Diluted EPS improved 3.0% YoY suggesting management cost reduction efforts despite operational losses
PYXS Stock Risks: Pyxis Oncology, Inc. Investment Risks
- Existential cash runway crisis: less than 3 months of liquidity at current $26M annual operating burn rate requires immediate capital raise or restructuring
- Revenue collapse with 14.2% YoY decline indicates failed product commercialization and deteriorating market position
- Unsustainable operating economics: $24.4M operating losses on only $13.9M revenue with negative 175.8% operating margin shows no viable business model currently
Key Metrics to Watch
- Quarterly cash balance and monthly burn rate - critical indicator of bankruptcy timeline and financing needs
- Revenue trajectory and new product authorization/launch status - only mechanism to restore viability
- Debt raise announcements and terms - dilution magnitude will indicate market confidence in company turnaround
Pyxis Oncology, Inc. (PYXS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.76x current ratio provides a solid financial cushion.
PYXS Profit Margin, ROE & Profitability Analysis
PYXS vs Healthcare Sector: How Pyxis Oncology, Inc. Compares
How Pyxis Oncology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pyxis Oncology, Inc. Stock Overvalued? PYXS Valuation Analysis 2026
Based on fundamental analysis, Pyxis Oncology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pyxis Oncology, Inc. Balance Sheet: PYXS Debt, Cash & Liquidity
PYXS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pyxis Oncology, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.32 indicates the company is currently unprofitable.
PYXS Revenue Growth, EPS Growth & YoY Performance
PYXS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.8M | -$21.2M | $-0.35 |
| Q2 2025 | $2.8M | -$3.3M | $-0.29 |
| Q1 2025 | $16.1M | -$3.3M | $-0.06 |
| Q3 2024 | $16.1M | -$21.2M | $-0.35 |
| Q2 2024 | $16.1M | -$3.3M | $-0.29 |
| Q1 2024 | $16.1M | -$3.3M | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pyxis Oncology, Inc. Dividends, Buybacks & Capital Allocation
PYXS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pyxis Oncology, Inc. (CIK: 0001782223)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PYXS
What is the AI rating for PYXS?
Pyxis Oncology, Inc. (PYXS) has an AI grade of D with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PYXS's key strengths?
Claude: Zero long-term debt (Debt/Equity 0.00x) eliminates financial leverage risk and refinancing concerns. Adequate working capital coverage with 2.76x current ratio provides near-term operational flexibility.
What are the risks of investing in PYXS?
Claude: Existential cash runway crisis: less than 3 months of liquidity at current $26M annual operating burn rate requires immediate capital raise or restructuring. Revenue collapse with 14.2% YoY decline indicates failed product commercialization and deteriorating market position.
What is PYXS's revenue and growth?
Pyxis Oncology, Inc. reported revenue of $13.9M.
Does PYXS pay dividends?
Pyxis Oncology, Inc. does not currently pay dividends.
Where can I find PYXS SEC filings?
Official SEC filings for Pyxis Oncology, Inc. (CIK: 0001782223) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PYXS's EPS?
Pyxis Oncology, Inc. has a diluted EPS of $-0.37.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PYXS's fundamental grade?
Based on our AI fundamental analysis in May 2026, Pyxis Oncology, Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PYXS stock overvalued or undervalued?
Valuation metrics for PYXS: ROE of -74.4% (sector avg: 15%), net margin of -167.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PYXS's AI grade for 2026?
Our dual AI analysis gives Pyxis Oncology, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PYXS's free cash flow?
Pyxis Oncology, Inc.'s operating cash flow is $-26.0M, with capital expenditures of $9.0K. FCF margin is -187.7%.
How does PYXS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -167.9% (avg: 12%), ROE -74.4% (avg: 15%), current ratio 2.76 (avg: 2).